Literature DB >> 7718898

Four new mutations in the NADH-cytochrome b5 reductase gene from patients with recessive congenital methemoglobinemia type II.

L M Vieira1, J C Kaplan, A Kahn, A Leroux.   

Abstract

Recessive congenital methemoglobinemia (RCM) due to NADH-cytochrome b5 reductase (cytb5r) deficiency leads to two different types of diseases. In the type I form, cyanosis is the only symptom, and the soluble enzyme is defective in red blood cells. In the type II form, cyanosis is associated with severe mental retardation and neurologic impairment; the enzymatic defect is systemic, involving both soluble and membrane-bound isoforms. We characterized mutations responsible for cytb5r deficiency in three unrelated patients with severe RCM type II. The first patient presented a homozygous exon 5 skipping. The only mutation detected was a homozygous G to C transversion at position +8, downstream from the 5' splice site of exon 5. We suggest that this unusual mutation might be responsible for the abnormal splicing of the primary transcripts, resulting in frameshift with premature STOP codon. The second mutation found corresponds to a homozygous C to T transition changing the Arg-218 codon to a premature STOP codon in exon 8. The third case was a compound heterozygote, carrying two different mutant alleles in the cyb5r gene. One allele presented a missense mutation with replacement of Cys-203 (TGC) by Arg (CGC) in exon 7. The second allele carried a 3-bp deletion (TGA) of nucleotides 815 to 817, modifying two contiguous codons in exon 9 of the cDNA with loss of Met-272. These results confirm the genetic polymorphism of cytb5r gene mutations identified in RCM type II, as observed for the mutations described in the RCM type I, and shed light on the molecular bases of the two different diseases associated with cytb5r deficiency.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7718898

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  4 in total

1.  Cloning and characterization of a maize cytochrome-b5 reductase with Fe3+-chelate reduction capability.

Authors:  P Bagnaresi; S Thoiron; M Mansion; M Rossignol; P Pupillo; J F Briat
Journal:  Biochem J       Date:  1999-03-01       Impact factor: 3.857

2.  A role for cytochrome b5 in the In vivo disposition of anticancer and cytochrome P450 probe drugs in mice.

Authors:  Colin J Henderson; Lesley A McLaughlin; Robert D Finn; Sebastien Ronseaux; Yury Kapelyukh; C Roland Wolf
Journal:  Drug Metab Dispos       Date:  2013-10-10       Impact factor: 3.922

3.  Neurological and Neuroimaging Features of CYB5R3-Related Recessive Hereditary Methemoglobinemia Type II.

Authors:  Francesco Nicita; Letizia Sabatini; Viola Alesi; Giulia Lucignani; Ester Sallicandro; Antonella Sferra; Enrico Bertini; Ginevra Zanni; Giuseppe Palumbo
Journal:  Brain Sci       Date:  2022-01-29

4.  Congenital methemoglobinemia type II in a 5-year-old boy.

Authors:  Elizabeth A Mannino; Thomas Pluim; Jacob Wessler; Megan T Cho; Jane Juusola; Samantha A Schrier Vergano
Journal:  Clin Case Rep       Date:  2017-12-07
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.